Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

19.85
+1.357.30%
Post-market: 19.990.1400+0.71%19:50 EDT
Volume:1.89M
Turnover:37.06M
Market Cap:1.92B
PE:-3.40
High:19.94
Open:18.75
Low:18.70
Close:18.50
52wk High:42.37
52wk Low:18.29
Shares:96.48M
Float Shares:92.79M
Volume Ratio:0.67
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8316
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-22.03%
PB:-23.94
PE(LYR):-3.40

Loading ...

Ultragenyx assumed with an Overweight at Barclays

TIPRANKS
·
Jan 28

AGCO Foundation Partners with the University of Sydney to Boost Resilience in Rural Communities

prnewswire
·
Jan 27

Ultragenyx Misses Primary Endpoints in Phase III Orbit and Cosmic Studies

Reuters
·
Jan 26

Ultragenyx Grants 16,355 Restricted Stock Units to New Employees

Reuters
·
Jan 26

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 24

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $25 From $23, Keeps Neutral Rating

MT Newswires Live
·
Jan 23

A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Upgraded 2025 Guidance And DTX401 BLA Completion

Simply Wall St.
·
Jan 15

Ultragenyx Pharmaceutical (RARE) Gets a Buy from Leerink Partners

TIPRANKS
·
Jan 14

Wedbush Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Jan 13

Ultragenyx Pharmaceutical Sees Higher 2025 Revenue

MT Newswires Live
·
Jan 12

Ultragenyx Pharmaceutical Shares up 2.8% Premarket After Preliminary FY25 Revenue Beats Estimates

THOMSON REUTERS
·
Jan 12

Ultragenyx provides corporate update, catalysts for 2026

TIPRANKS
·
Jan 12

BRIEF-Ultragenyx Provides Financial And Business Updates At J.P. Morgan Annual Healthcare Conference

Reuters
·
Jan 12

Ultragenyx Pharmaceutical Inc - Cash and Investments About $735 Mln as of Dec 31, 2025

THOMSON REUTERS
·
Jan 12

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

GlobeNewswire
·
Jan 12

Ultragenyx price target lowered to $50 from $55 at Morgan Stanley

TIPRANKS
·
Jan 08

RBC Cuts Price Target on Ultragenyx Pharmaceutical to $35 From $72, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 08

Ultragenyx CFO Howard Horn Reports Sale of Common Shares

Reuters
·
Jan 06

Ultragenyx Pharma Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 05

Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide

Benzinga_recent_news
·
Jan 03